Objectives: The aim of this study was to assess 25-hydroxyvitamin D (vitamin D) status in an HIV-infected adult population and to define HIV-and antiretroviral-related factors associated with vitamin D deficiency.
Introduction
Epidemiological data indicate that a low level of vitamin D is associated with an increased risk of musculoskeletal complaints, including osteomalacia and osteoporosis. 1 It may also contribute to a number of pathological processes, such as immune dysfunction, inflammation, autoimmune diseases, cardiovascular diseases and malignancies. 2 -4 These effects could explain in part why, in the general population, morbidity and mortality are significantly more frequent in subjects with vitamin D deficiency. 5, 6 Most of the morbidities associated with a low level of vitamin D have been reported to have a high prevalence in the HIV-infected population, in particular regarding bone mineral metabolism. As some studies have reported an incidence of osteopenia and osteoporosis greater than in the general population matched for age and sex, the evaluation of bone metabolism alteration is an important issue in the HIV population. 7 -10 Some antiretroviral drugs, such as tenofovir and some protease inhibitors, are known to have an impact on bone metabolism. 11 -13 Studies focusing on vitamin D are therefore of interest because they might provide a link to the high prevalence of abnormalities of bone mineral metabolism in the HIV-infected population and objectivize the effect that antiretroviral drugs may have on vitamin D levels.
Recently, results from the EuroSIDA cohort and the ICONA study demonstrated that vitamin D deficiency was independently associated with a higher risk of death and AIDS events. 14, 15 The SUN study showed that vitamin D insufficiency and deficiency were highly prevalent in an HIV-infected adult population, although less prevalent than in the general population, and were associated with exposures to certain antiretroviral drugs, such as efavirenz and ritonavir. 16 Studies on the relationship between vitamin D status, HIV infection and the impact of antiretroviral therapies have been performed on cohorts of HIV-infected patients, but mostly in heterogeneous populations or using a limited sample size. 15, 17, 18 In fact, the effects of individual protease inhibitors (PIs) on vitamin D level, in particular vitamin D deficiency, are still unclear.
This study assessed vitamin D status and aimed to define HIV-and antiretroviral-related factors associated with vitamin D deficiency in a large French HIV-infected adult population.
Methods

Study design
Information was collected from five large HIV reference centres in France participating in the Dat'AIDS cohort (Nantes, 47812
′ N 2820 ′ E; and Toulouse, 43837 ′ N 1827 ′ E). These centres maintain prospective cohorts of all HIV-1-infected patients who provided written consent. The cohorts are implemented via a common electronic medical record (EMR). 19 The patients enter the cohort when they seek care in one of the centres, regardless of their HIV disease history, and all previous clinical events as well as therapeutic history are collected with appropriate dates. The EMR collects demographic details, clinical events, antiretroviral history, viral load and CD4 cell count data at regular 3 -6 month intervals during routine clinical assessment. This system allows the use of the databases with minimal delay, apart from automatic and manual quality controls performed before any analysis.
For the purpose of this cross-sectional study, we included centres in which 25% of the patients had routine 25-hydroxyvitamin D (vitamin D) levels measured between January 2007 and June 2010.
Patients
To evaluate the impact of antiretroviral drugs, adult patients were included if they were either antiretroviral naive or were receiving a stable antiretroviral regimen for .3 months. Patients receiving vitamin D supplementation, treatment for osteoporosis, on renal dialysis or with creatininaemia .400 mmol/L at time of the vitamin D measurement were excluded. The estimated glomerular filtration rate (eGFR) was obtained using the Modification of Diet in Renal Disease (MDRD) formula. An eGFR cut-off of 90 mL/min/1.73 m 2 was chosen in our study with respect to the definition of stage 2 chronic kidney disease. 20 
Data collection
Measurement of vitamin D and definitions
Serum vitamin D, which is the best indicator of vitamin D status, was measured using radioimmunoassay (DiaSorin, normal range 30-100 ng/mL) in four centres and electrochemoluminescence (Cobas Roche, normal range 30-80 ng/mL) in one centre (10% of the subjects). A validated quality/control process was performed in all the centres.
Low-level vitamin D concentration was defined as ,30 ng/mL. Vitamin D insufficiency and deficiency were defined as vitamin D between .10 and ,30 ng/mL, and ≤10 ng/mL, respectively. 21 
Statistical analysis
Characteristics of the population and the prevalence of vitamin D deficiency are presented for the whole population and separately in antiretroviral-naive and -treated patients. Variables were described using the median and IQR for quantitative variables and proportions for qualitative variables.
Then we performed a logistic regression model to identify variables associated with vitamin D deficiency (≤10 versus .10 ng/mL). Variables with a P value ,0.20 in univariate analysis were included in the logistic regression model, except for age, which was forced in the model. Treatment was considered in three steps in separate models: first as a binary variable (treated or naive); then, in case of significance, as a combination of drugs [two nucleoside reverse transcriptase inhibitors (NRTIs)+one boosted PI, two NRTIs+one non-nucleoside reverse transcriptase inhibitor (NNRTI) or other] and drug by drug among only antiretroviral-treated patients. The x 2 test was used to test categorical variables and the Kruskal-Wallis test was used for continuous variables. Associations were assessed using adjusted ORs (aORs) and corresponding 95% CIs for logistic regression. The season of vitamin D measurement was adjusted for logistic regression in the multivariate models.
For the subsample with a measure of PTH at the same time as the measure of vitamin D, the median and IQR of PTH were estimated according to the level of vitamin D, eGFR and treatment.
Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
Results
Five centres participated in the study, contributing a total of 7065 eligible participants. Of these, 3570 patients had at least one measurement of vitamin D level determined between January 2007 and June 2010. Among these, 508 had received antiretroviral treatment for ,3 months and were therefore excluded. Respectively, 60 patients had a history of osteoporosis and 8 a history of severe renal impairment, and were also excluded. The study thus included 2994 patients, 334 being antiretroviral naive and 2660 being treated with a stable regimen for .3 months. Patients had a median age of 45 years, were predominantly male (72.3%), with a median nadir CD4 count of 203 cells/mm 3 (IQR 101 -303) and median time since HIV diagnosis of 11.6 years (IQR 5.5 -17.6), and 18% were HBV or HCV coinfected. No vitamin D gradient was found between sites located at higher and lower latitudes, at 508 N and 438 N, respectively. Baseline patient characteristics at the time of vitamin D measurement are shown in (Table 3) . Compared with a vitamin D measurement performed in autumn, measurement performed in summer was associated with a lower probability of vitamin D deficiency [aOR 0.27 (0.18 -0.40)] and measurement in winter with a higher probability of vitamin D deficiency [aOR 1.95 (1.54 -2.47)]. Prior AIDS was not associated with vitamin D deficiency ( Table 3) .
As antiretroviral treatment was associated with deficiency, analyses were then conducted in treated patients. The 2660 antiretroviral-treated subjects had been receiving treatment for a median of 9.6 years (IQR 4.5-13.1) and had been on their current regimen for a median of 18 months (IQR 9 -35); 34.6% of the patients received a combination with two NRTIs + one NNRTI and 40.2% a combination with two NRTIs+one boosted PI. Allavena et al.
In univariate analysis, besides the same factors found in the whole study population, a higher median duration of the current treatment, being treated with two NRTIs + one NNRTI and receiving a regimen including zidovudine, lamivudine, emtricitabine, abacavir, efavirenz or ritonavir were statistically associated with vitamin D deficiency. A regimen including tenofovir or darunavir was associated with a lower risk of vitamin D deficiency (Table 4) .
In multivariate analysis, vitamin D deficiency was significantly associated with an NNRTI-based regimen compared with a boosted PI-based regimen [aOR 1.53 (1.22 -1.92)]. The only antiretroviral drug associated with a vitamin D deficiency was efavirenz [aOR 1.89 (1.45 -2.47)] (Table 4) . No association was found between vitamin D deficiency and the other available NNRTIs (nevirapine and etravirine), any nucleoside analogue, including zidovudine and tenofovir, any boosted protease inhibitor or raltegravir. By considering the duration of exposure to antiretroviral drugs, we observed the same associations as in our model using antiretroviral drugs as a binary variable (data not shown), the duration of exposure to efavirenz being the only drug exposure associated with an increased risk of deficiency [aOR 1.02 (1.01 -1.03)].
Among the 2994 patients, 1067 had a measure of PTH at the time of vitamin D measurement. These patients were comparable to patients without PTH measurement except for sites, hepatitis coinfection, antiretroviral status and season of vitamin D measurement. Median PTH level was 39. (Table 2 ). Among antiretroviral-treated patients with a PTH measurement (n¼ 971), no effect of drug classes (2 NRTIs + 1 boosted PI versus 2 NRTIs + 1 NNRTI) and no effect of tenofovir on PTH concentration were found in our study (data not shown).
Discussion
The present study documents the high prevalence of vitamin D insufficiency and deficiency in a French cohort of HIV-infected adult subjects. Overall, 86% of the study population had a low level of vitamin D and 31% a vitamin D deficiency. This result is concordant with the Swiss cohort, where vitamin D deficiency occurred in 14% -52% of 211 HIV-infected subjects according to the season of the measurement. 22 It seems more frequent than in an Italian HIV-infected population (ICONA study), in which vitamin D deficiency was documented from 6% to 9% according to the season, and in the general population, in which it has been evaluated as 14% in France and ,10% in the USA. 14, 16, 23, 24 However, comparison with the general population would need to be re-evaluated in a new age-and gender-matched study since recent data from the NHANES studies have shown deterioration of vitamin D status over the last decade in the general population. 25 Consistent with earlier reports in the general population, smoking and measurement in winter were strongly related to low levels of vitamin D. Exposure to antiretroviral therapy was also associated with vitamin D deficiency. However, in the multivariate analysis, BMI, time since HIV diagnosis and previous AIDS did not affect the level of vitamin D; Vitamin D deficiency and antiretroviral drugs 2225 JAC nor did ageing, although it is a well-recognized factor for vitamin D deficiency in the general population. This may be due to the fact that patients included in HIV cohorts are younger than the general population, with very few patients over 60.
Our results focused on vitamin D deficiency ≤10 ng/mL because this threshold has been shown to be more frequently associated with clinical manifestations and should have clinical relevance. 14, 15, 24 Epidemiological studies have indeed demonstrated an association between vitamin D deficiency and an overall increased risk of mortality in healthy populations. 1, 5 In an HIV-infected adult population, analysis of the EuroSIDA cohort confirmed the clinical relevance of vitamin D levels Sample too small for zalcitabine (n¼0), stavudine (n¼11), delavirdine (n ¼0), indinavir (n ¼7), nelfinavir (n¼2), tipranavir (n¼4) and enfuvirtide (n ¼4). *x 2 test. **Kruskal-Wallis test. Model adjusted also on care centre.
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,12 ng/mL with an increased risk of an AIDS event or death in these patients. 15 In our study patients with CD4 ,200 cells/mm 3 had a 2-fold higher risk of vitamin D deficiency compared with patients with CD4 ,350 cells/mm 3 . These results are consistent with the EuroSIDA cohort as immunodepression is associated with AIDS clinical manifestation and death.
Our study demonstrates that antiretroviral-treated patients are at higher risk of vitamin D deficiency and is, to our knowledge, the largest to evaluate the impact of each commonly used antiretroviral drug, including the most recently available molecules (etravirine, darunavir and raltegravir). Neither raltegravir nor any PI was related to the vitamin D level. An effect of NNRTIs on vitamin D has been found in some previous studies with a small sample size that precluded the inclusion of individual NNRTIs in the multivariate analysis. 22,26 -28 Our study clearly shows that, within the NNRTI class, only efavirenz is a risk factor for vitamin D deficiency. The negative effect of efavirenz on vitamin D has been suggested in the MONET trial, in which patients showed a higher increase in vitamin D over 96 weeks when they stopped efavirenz or zidovudine rather than other antiretrovirals. In the Phase 3 ECHO trial a significant decrease in vitamin D occurred in patients treated with efavirenz but not with rilpivirine over 48 weeks. 29, 30 Efavirenz has been shown to reduce the expression of cytochrome P450 2RI, one of the enzymes involved in the 25-hydroxylation of vitamin D3, and to induce cytochrome 24, which converts vitamin D and calcitriol into their inactive metabolites. 26, 28, 31 Although a high incidence of osteopenia/osteoporosis has been observed in patients receiving a PI-based therapy, a cause-and-effect relationship has not been clearly established. In vitro ritonavir impaired 25-hydroxylase activity in a human hepatocyte cell line and inhibited enzymes for calcitriol synthesis and catabolism in human macrophages, but no dramatic decrease in vitamin D levels was observed in patients treated with PI. 28 In our study, vitamin D level was not modified in patients receiving a PI-based regimen. The effect of NRTI drugs on vitamin D metabolism has never been studied but interactions are unlikely as NRTIs are not known to be cytochrome P450 modifiers. Tenofovir is known to induce a proximal renal tubular dysfunction that could reduce the effect of 1a-hydroxylase in the kidney, which metabolizes vitamin D into the active form of 1,25-hydroxyvitamin D, leading to vitamin D accumulation. In concordance with the SUN study, we found a statistical negative association between vitamin D level and tenofovir using a linear regression analysis (data not shown). 16 The association between tenofovir and less frequent vitamin D deficiency did not persist in the multivariate analysis, which could reflect either a mild effect of tenofovir or a confounding effect of others drugs. Several cases of hyperparathyroidism have recently been reported in HIV-infected patients treated with tenofovir. 32, 33 No hyperparathyroidism was seen in our study even in patients receiving tenofovir. Vitamin D deficiency was associated with higher PTH concentrations that nonetheless remained within the normal range. Furthermore, no association was shown between PTH and tenofovir. Although not statistically significant, the results of the Swiss cohort are similar to those reported here. 22 Surprisingly, but concordantly with the SUN study, vitamin D deficiency was negatively associated with an eGFR ≥90 mL/min/1.73 m 2 . 16 Of note, a large majority of patients had normal or mildly impaired renal function. However, PTH was inversely correlated with a lower eGFR, as expected. We expect that in renal disease stage 2 and 3, a mild impairment of the enzyme 1a-hydroxylase could lead to an accumulation of vitamin D. Data on 1,25-hydroxyvitamin D were missing in our study and could have been useful in explaining these results. Our study has several limitations. Some data that could represent potential confounding factors, such as sun exposure, socioeconomic factors, ethnicity and dark-coloured skin, were not routinely captured in our database, Measurement of 1,25-hydroxyvitamin D could also be informative for better interpretation of some results but it was not routinely prescribed. Due to the data collection method, it is possible that the clinician did not fully capture over-the-counter multi-vitamin supplements containing vitamin D, or even vitamin D supplementation provided by another physician. In the same way, some characteristics that we did not capture could play a confounding role, particularly regarding the unexpected association between eGFR and vitamin D concentration. As our sample represents 42.4% of the eligible population, a selection bias is always possible, limiting the applicability of our results to the whole HIV population of the five centres participating in the study.
In summary, our study confirms the high frequency of vitamin D deficiency in HIV-infected patients. It is very challenging to separate HIV-related factors, including antiretroviral-related factors, from the confounding risk factors, which are over-represented in the HIV-infected population. Apart from risk factors that are well known in the general population, antiretroviral therapy, and particularly the use of efavirenz but not tenofovir, increased the probability of vitamin D deficiency. None of the newer antiretroviral drugs seems to have an impact on vitamin D status. Further studies are needed to evaluate the impact of switching antiretroviral treatment and/or vitamin D supplementation on vitamin D levels and their clinical consequences in an HIV-infected population.
